Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Average (2016 - 2025)

Ani Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at $523.3 million for Q4 2025.

  • For Q4 2025, Equity Average rose 173.28% year-over-year to $523.3 million; the TTM value through Dec 2025 reached $523.3 million, up 173.28%, while the annual FY2025 figure was $472.2 million, 128.93% up from the prior year.
  • Equity Average for Q4 2025 was $523.3 million at Ani Pharmaceuticals, up from $214.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $523.3 million in Q4 2025 and bottomed at -$96.8 million in Q1 2023.
  • The 5-year median for Equity Average is $193.5 million (2021), against an average of $135.9 million.
  • The largest YoY upside for Equity Average was 4803.41% in 2023 against a maximum downside of 149.55% in 2023.
  • A 5-year view of Equity Average shows it stood at $289.6 million in 2021, then tumbled by 132.79% to -$95.0 million in 2022, then soared by 62.08% to -$36.0 million in 2023, then surged by 631.72% to $191.5 million in 2024, then skyrocketed by 173.28% to $523.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Equity Average are $523.3 million (Q4 2025), $214.5 million (Q3 2025), and -$36.6 million (Q2 2025).